PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 09/30/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. IPSC, CALC, LVTX, ANVS, TPST, TLPH, XLO, VRCA, XFOR, and GBIOShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Century Therapeutics (IPSC), CalciMedica (CALC), LAVA Therapeutics (LVTX), Annovis Bio (ANVS), Tempest Therapeutics (TPST), Talphera (TLPH), Xilio Therapeutics (XLO), Verrica Pharmaceuticals (VRCA), X4 Pharmaceuticals (XFOR), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Its Competitors Century Therapeutics CalciMedica LAVA Therapeutics Annovis Bio Tempest Therapeutics Talphera Xilio Therapeutics Verrica Pharmaceuticals X4 Pharmaceuticals Generation Bio PHAXIAM Therapeutics (NASDAQ:PHXM) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership. Is PHXM or IPSC more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to Century Therapeutics' net margin of -19.10%. PHAXIAM Therapeutics' return on equity of 0.00% beat Century Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A Century Therapeutics -19.10%-11.53%-6.94% Which has stronger valuation and earnings, PHXM or IPSC? PHAXIAM Therapeutics has higher earnings, but lower revenue than Century Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM TherapeuticsN/AN/A-$240KN/AN/ACentury Therapeutics$6.59M6.50-$126.57M-$0.29-1.71 Does the media refer more to PHXM or IPSC? In the previous week, Century Therapeutics' average media sentiment score of 1.89 beat PHAXIAM Therapeutics' score of 0.00 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment PHAXIAM Therapeutics Neutral Century Therapeutics Very Positive Which has more volatility and risk, PHXM or IPSC? PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Do analysts prefer PHXM or IPSC? Century Therapeutics has a consensus target price of $3.75, indicating a potential upside of 656.05%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Century Therapeutics is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Century Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in PHXM or IPSC? 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Comparatively, 5.0% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryCentury Therapeutics beats PHAXIAM Therapeutics on 7 of the 12 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$233.52M$6.01B$10.54BDividend YieldN/A3.80%5.92%4.70%P/E RatioN/A31.8176.7726.37Price / SalesN/A5,631.43583.98127.43Price / CashN/A13.1938.1961.33Price / Book0.39109.0512.516.41Net Income-$240K-$90.99M$3.30B$277.11M7 Day PerformanceN/A1.52%28,039.44%1.07%1 Month PerformanceN/A5.82%30,444.22%7.43%1 Year PerformanceN/A568.28%35,707.86%35.04% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049IPSCCentury Therapeutics3.1794 of 5 stars$0.51+4.4%$3.75+636.6%-69.7%$42.13M$6.59M-1.76170Positive NewsCALCCalciMedica2.751 of 5 stars$3.08+2.3%$16.00+419.5%-27.7%$42.06MN/A-1.9230Positive NewsLVTXLAVA Therapeutics1.9161 of 5 stars$1.59+0.1%$2.69+68.9%-7.8%$41.78M$11.98M-1.5160Gap DownANVSAnnovis Bio2.3518 of 5 stars$1.98-7.3%$17.33+777.6%-73.0%$41.51MN/A-0.973Analyst ForecastHigh Trading VolumeTPSTTempest Therapeutics2.5385 of 5 stars$9.38+0.8%$30.00+219.8%-41.3%$41.34MN/A-0.6420Positive NewsGap UpTLPHTalphera1.8166 of 5 stars$0.91+0.5%$5.00+451.6%+10.0%$41.12M$650K-2.2719Short Interest ↑XLOXilio Therapeutics2.3133 of 5 stars$0.80+4.8%$3.00+276.9%+11.0%$39.35M$6.34M-1.0570Positive NewsVRCAVerrica Pharmaceuticals4.196 of 5 stars$4.18+2.2%$80.00+1,813.9%-67.6%$38.63M$7.57M-0.5040Positive NewsXFORX4 Pharmaceuticals4.4375 of 5 stars$3.46+2.4%$34.17+887.5%-81.0%$38.56M$2.56M-0.2380Positive NewsGBIOGeneration Bio4.1107 of 5 stars$6.00+4.9%$10.67+77.8%-74.4%$38.53M$19.89M-0.55150Positive News Related Companies and Tools Related Companies Century Therapeutics Competitors CalciMedica Competitors LAVA Therapeutics Competitors Annovis Bio Competitors Tempest Therapeutics Competitors Talphera Competitors Xilio Therapeutics Competitors Verrica Pharmaceuticals Competitors X4 Pharmaceuticals Competitors Generation Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 10/2/2025 by MarketBeat.com Staff From Our PartnersThe Army Just Got a New Drone SupplierThis innovative drone developer has been selected to supply its Flex FPV Modular Drones to the U.S. Army. T...The Tomorrow Investor | SponsoredExpert Alert: Massive Bubble Could Crash Your WealthOn July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Biotech has a clinical approach that intrigues investorsThis biotech is gearing up for Phase 2 trials with a strategy to unlock multiple approvals from one study. ...i2i Marketing Group, LLC | SponsoredFree: The Crypto Summit That Could Change Your LifeFed cuts unleash crypto's next wave The smart money is already moving. This is your chance to see their car...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
